Research ExplorerPublicationsMetabolomic Profiling in Relation to New-Onset Atrial Fibril...

Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study)

Standard

Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study). / Ko, Darae; Riles, Eric M; Marcos, Ernaldo G; Magnani, Jared W; Lubitz, Steven A; Lin, Honghuang; Long, Michelle T; Schnabel, Renate B; McManus, David D; Ellinor, Patrick T; Ramachandran, S Vasan; Wang, Thomas J; Gerszten, Robert E; Benjamin, Emelia J; Yin, Xiaoyan; Rienstra, Michiel.

In: AM J CARDIOL, Vol. 118, No. 10, 15.11.2016, p. 1493-1496.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ko, D, Riles, EM, Marcos, EG, Magnani, JW, Lubitz, SA, Lin, H, Long, MT, Schnabel, RB, McManus, DD, Ellinor, PT, Ramachandran, SV, Wang, TJ, Gerszten, RE, Benjamin, EJ, Yin, X & Rienstra, M 2016, 'Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study)', AM J CARDIOL, vol. 118, no. 10, pp. 1493-1496. https://doi.org/10.1016/j.amjcard.2016.08.010

APA

Ko, D., Riles, E. M., Marcos, E. G., Magnani, J. W., Lubitz, S. A., Lin, H., Long, M. T., Schnabel, R. B., McManus, D. D., Ellinor, P. T., Ramachandran, S. V., Wang, T. J., Gerszten, R. E., Benjamin, E. J., Yin, X., & Rienstra, M. (2016). Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study). AM J CARDIOL, 118(10), 1493-1496. https://doi.org/10.1016/j.amjcard.2016.08.010

Vancouver

Ko D, Riles EM, Marcos EG, Magnani JW, Lubitz SA, Lin H et al. Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study). AM J CARDIOL. 2016 Nov 15;118(10):1493-1496. https://doi.org/10.1016/j.amjcard.2016.08.010

Bibtex

@article{90ef1dc854954890abdeda6318537596,
title = "Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study)",
abstract = "Previous studies have shown several metabolic biomarkers to be associated with prevalent and incident atrial fibrillation (AF), but the results have not been replicated. We investigated metabolite profiles of 2,458 European ancestry participants from the Framingham Heart Study without AF at the index examination and followed them for 10 years for new-onset AF. Amino acids, organic acids, lipids, and other plasma metabolites were profiled by liquid chromatography-tandem mass spectrometry using fasting plasma samples. We conducted Cox proportional hazard analyses for association between metabolites and new-onset AF. We performed hypothesis-generating analysis to identify novel metabolites and hypothesis-testing analysis to confirm the previously reported associations between metabolites and AF. Mean age was 55.1 ± 9.9 years, and 53% were women. Incident AF developed in 156 participants (6.3%) in 10 years of follow-up. A total of 217 metabolites were examined, consisting of 54 positively charged metabolites, 59 negatively charged metabolites, and 104 lipids. None of the 217 metabolites met our a priori specified Bonferroni corrected level of significance in the multivariate analyses. We were unable to replicate previous results demonstrating associations between metabolites that we had measured and AF. In conclusion, in our metabolomics approach, none of the metabolites we tested were significantly associated with the risk of future AF.",
keywords = "Atrial Fibrillation/blood, Biomarkers/blood, Chromatography, Liquid, Europe/epidemiology, Female, Follow-Up Studies, Humans, Incidence, Male, Mass Spectrometry, Metabolomics/methods, Middle Aged, Recurrence, Retrospective Studies, Risk Assessment/methods, Risk Factors, Time Factors",
author = "Darae Ko and Riles, {Eric M} and Marcos, {Ernaldo G} and Magnani, {Jared W} and Lubitz, {Steven A} and Honghuang Lin and Long, {Michelle T} and Schnabel, {Renate B} and McManus, {David D} and Ellinor, {Patrick T} and Ramachandran, {S Vasan} and Wang, {Thomas J} and Gerszten, {Robert E} and Benjamin, {Emelia J} and Xiaoyan Yin and Michiel Rienstra",
note = "Copyright {\textcopyright} 2016 Elsevier Inc. All rights reserved.",
year = "2016",
month = nov,
day = "15",
doi = "10.1016/j.amjcard.2016.08.010",
language = "English",
volume = "118",
pages = "1493--1496",
journal = "AM J CARDIOL",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study)

AU - Ko, Darae

AU - Riles, Eric M

AU - Marcos, Ernaldo G

AU - Magnani, Jared W

AU - Lubitz, Steven A

AU - Lin, Honghuang

AU - Long, Michelle T

AU - Schnabel, Renate B

AU - McManus, David D

AU - Ellinor, Patrick T

AU - Ramachandran, S Vasan

AU - Wang, Thomas J

AU - Gerszten, Robert E

AU - Benjamin, Emelia J

AU - Yin, Xiaoyan

AU - Rienstra, Michiel

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Previous studies have shown several metabolic biomarkers to be associated with prevalent and incident atrial fibrillation (AF), but the results have not been replicated. We investigated metabolite profiles of 2,458 European ancestry participants from the Framingham Heart Study without AF at the index examination and followed them for 10 years for new-onset AF. Amino acids, organic acids, lipids, and other plasma metabolites were profiled by liquid chromatography-tandem mass spectrometry using fasting plasma samples. We conducted Cox proportional hazard analyses for association between metabolites and new-onset AF. We performed hypothesis-generating analysis to identify novel metabolites and hypothesis-testing analysis to confirm the previously reported associations between metabolites and AF. Mean age was 55.1 ± 9.9 years, and 53% were women. Incident AF developed in 156 participants (6.3%) in 10 years of follow-up. A total of 217 metabolites were examined, consisting of 54 positively charged metabolites, 59 negatively charged metabolites, and 104 lipids. None of the 217 metabolites met our a priori specified Bonferroni corrected level of significance in the multivariate analyses. We were unable to replicate previous results demonstrating associations between metabolites that we had measured and AF. In conclusion, in our metabolomics approach, none of the metabolites we tested were significantly associated with the risk of future AF.

AB - Previous studies have shown several metabolic biomarkers to be associated with prevalent and incident atrial fibrillation (AF), but the results have not been replicated. We investigated metabolite profiles of 2,458 European ancestry participants from the Framingham Heart Study without AF at the index examination and followed them for 10 years for new-onset AF. Amino acids, organic acids, lipids, and other plasma metabolites were profiled by liquid chromatography-tandem mass spectrometry using fasting plasma samples. We conducted Cox proportional hazard analyses for association between metabolites and new-onset AF. We performed hypothesis-generating analysis to identify novel metabolites and hypothesis-testing analysis to confirm the previously reported associations between metabolites and AF. Mean age was 55.1 ± 9.9 years, and 53% were women. Incident AF developed in 156 participants (6.3%) in 10 years of follow-up. A total of 217 metabolites were examined, consisting of 54 positively charged metabolites, 59 negatively charged metabolites, and 104 lipids. None of the 217 metabolites met our a priori specified Bonferroni corrected level of significance in the multivariate analyses. We were unable to replicate previous results demonstrating associations between metabolites that we had measured and AF. In conclusion, in our metabolomics approach, none of the metabolites we tested were significantly associated with the risk of future AF.

KW - Atrial Fibrillation/blood

KW - Biomarkers/blood

KW - Chromatography, Liquid

KW - Europe/epidemiology

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Incidence

KW - Male

KW - Mass Spectrometry

KW - Metabolomics/methods

KW - Middle Aged

KW - Recurrence

KW - Retrospective Studies

KW - Risk Assessment/methods

KW - Risk Factors

KW - Time Factors

U2 - 10.1016/j.amjcard.2016.08.010

DO - 10.1016/j.amjcard.2016.08.010

M3 - SCORING: Journal article

C2 - 27666170

VL - 118

SP - 1493

EP - 1496

JO - AM J CARDIOL

JF - AM J CARDIOL

SN - 0002-9149

IS - 10

ER -